Quantum Private Wealth LLC Has $212,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

Quantum Private Wealth LLC lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,124 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the quarter. Quantum Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $212,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Tyche Wealth Partners LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $349,000. HealthInvest Partners AB acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $4,515,000. Everence Capital Management Inc. increased its position in shares of Bristol-Myers Squibb by 20.9% in the fourth quarter. Everence Capital Management Inc. now owns 83,350 shares of the biopharmaceutical company’s stock worth $4,277,000 after purchasing an additional 14,424 shares during the period. SVB Wealth LLC raised its stake in Bristol-Myers Squibb by 0.4% in the fourth quarter. SVB Wealth LLC now owns 93,443 shares of the biopharmaceutical company’s stock valued at $4,795,000 after purchasing an additional 367 shares in the last quarter. Finally, Crescent Grove Advisors LLC lifted its position in Bristol-Myers Squibb by 10.2% during the fourth quarter. Crescent Grove Advisors LLC now owns 11,825 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 1,095 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Down 0.5 %

Shares of NYSE BMY traded down $0.25 during trading on Wednesday, reaching $48.26. The company had a trading volume of 11,931,277 shares, compared to its average volume of 10,940,481. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock has a market cap of $97.81 billion, a P/E ratio of 12.50, a PEG ratio of 1.46 and a beta of 0.39. The company’s fifty day moving average price is $51.27 and its 200-day moving average price is $51.62.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 EPS. As a group, research analysts expect that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Analyst Ratings Changes

Several equities analysts have recently commented on BMY shares. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Wells Fargo & Company dropped their price objective on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.